biostudies-literatureMayne KJClinical Trial Service Unit and Epidemiological Studies UnitMedical Research Council720-730https://www.ebi.ac.uk/biostudies/studies/S-EPMC7616479biostudies-literatureUnknown40(4)<h4>Background</h4>Hyperuricaemia and gout are common in chronic kidney disease (CKD). We aimed to assess the effects of sodium-glucose co-transporter-2 (SGLT2) inhibition on uric acid (urate) and gout in patients with CKD.<h4>Methods</h4>The EMPA-KIDNEY trial randomised 6609 patients with CKD to receive either empagliflozin 10 mg daily or matching placebo over a median of 2 years of follow-up. Serum uric acid was measured at randomisation then at 2 and 18 months of follow-up and the effects of empagliflozin were analysed using a pre-specified mixed model repeated measures approach. Participant-reported gout events were analysed in Cox regression models (first events) with the Andersen-Gill extension (total events). A post hoc composite outcome included new initiation of uric acid-loweringNephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal AssociationEmpagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial.PMC7616479MC_UU_00017/4MC_UU_00017/3Green JBGeorge JHooi LPontremoli RCheung AKNg SYAJudge PHaynes RKadowaki TNangaku MJudge PKGoto SDeo RWanner CLiu WSammons EHerrington WGWhelton PBaigent CEMPA-KIDNEY Collaborative GroupRossello XSardell RJLandray MJEmberson JHauske SJLevin ABilous RHantel SLi JBennett DBrueckmann MCherney DHopley Mvon-Eynatten MMayne KJZhu DTuttle KRMaggioni APPreiss DWittes JSandercock PCherney DZIStaplin NLiu ZHHerzog CfalseEmpagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial.<h4>Background</h4>Hyperuricaemia and gout are common in chronic kidney disease (CKD). We aimed to assess the effects of sodium-glucose co-transporter-2 (SGLT2) inhibition on uric acid (urate) and gout in patients with CKD.<h4>Methods</h4>The EMPA-KIDNEY trial randomised 6609 patients with CKD to receive either empagliflozin 10 mg daily or matching placebo over a median of 2 years of follow-up. Serum uric acid was measured at randomisation then at 2 and 18 months of follow-up and the effects of empagliflozin were analysed using a pre-specified mixed model repeated measures approach. Participant-reported gout events were analysed in Cox regression models (first events) with the Andersen-Gill extension (total events). A post hoc composite outcome included new initiation of uric acid-lowering2025-01-01T00:00:00Z2025 Apr2026-06-03T05:18:10.106Z2025-04-04T08:21:43.669ZS-EPMC76164793927778410.1093/ndt/gfae203